In 2023, CStone Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, CStone Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 0a | 0a | 0b | |
Total Scope 2 | ||||
Unspecified Calculation Method | 446.63a | 506.3a | 452.31b | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0a | 0a | 0b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of CStone Pharmaceuticals amounted to 446.63 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of CStone Pharmaceuticals decreased by 11.79%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2023, the total Scope 1 emissions of CStone Pharmaceuticals were 0 metric tons of CO₂ equivalent (tCO₂e).a
In 2023, CStone Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 446.63 tCO₂e without specifying the calculation method.a
Since 2020, CStone Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that CStone Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2022), CStone Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) fell by 11.79% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2023, CStone Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a